Abivax SA (ABVX)
ABVX moved a median of -0.35% 30 minutes after news, and -0.47% by the close. How ABVX actually reacts to news — the realized, point-in-time move the market made, measured across 97 labeled events over the last three years with zero look-ahead.
ABVX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.12% | 44% | 92 |
| 30-min | -0.35% | 43% | 96 |
| 60-min | -0.37% | 43% | 97 |
| to close | -0.47% | 38% | 96 |
| Middle 50% of ABVX reactions | -1.16% to +1.23% |
|---|---|
| Median reaction (30-min) | -0.35% |
| Measured reactions | 97 |
Half of all Abivax SA news events land between -1.16% and +1.23% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ABVX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.41% | 33% | -3.94% |
| Coverage initiations | 41 | -1.27% | 22% | -0.92% |
| Rating reiterations | 61 | -0.41% | 36% | -0.43% |
| Price-target raises | 15 | +0.96% | 60% | +0.58% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how ABVX ranks against every other measured name →
That’s how ABVX usually reacts — get an email when it moves on news →Email me when ABVX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABVX's baseline. Nothing else.
Recent ABVX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | Press release | GlobeNewswire | -2.29% | -1.84% | |
| Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments | Press release | GlobeNewswire | -1.11% | -5.59% | |
| Abivax Announces Closing of $920 Million Public Offering | Press release | GlobeNewswire | -0.13% | -0.23% | |
| Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) | Press release | GlobeNewswire | +1.49% | +4.44% | |
| Form 6-K Abivax S.A. For: Jul 02 | SEC filing · Form 6-K | SEC EDGAR | -0.33% | -1.48% | |
| Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares | Press release | GlobeNewswire | -1.02% | -3.94% | |
| Abivax announces temporary trading halt of its ordinary shares on Euronext Paris | Press release | GlobeNewswire | -1.02% | -3.94% | |
| Abivax announces trading resumption of its ordinary shares on Euronext Paris | Press release | GlobeNewswire | -1.02% | -3.94% | |
| Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares | Press release | GlobeNewswire | -1.02% | -3.94% | |
| Abivax Announces Launch of Public Offering of American Depositary Shares | Press release | GlobeNewswire | -1.02% | -3.94% | |
| Form POSASR Abivax S.A. | SEC filing · Form POSASR | SEC EDGAR | -1.02% | -3.94% | |
| Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database | Press release | GlobeNewswire | +0.25% | +1.73% | |
| Form 6-K Abivax S.A. For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | +1.73% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Abivax S.A. (ABVX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.71% | +2.58% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Abivax S.A. (ABVX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.33% | -0.62% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Abivax S.A. (ABVX) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.09% | -2.29% | |
| Abivax S.A. (ABVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -1.79% | -1.34% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Abivax S.A. (ABVX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.94% | +3.06% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Abivax S.A. (ABVX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.07% | +2.31% | |
| Abivax S.A. (ABVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.15% | +0.36% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Abivax S.A. (ABVX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.34% | -0.07% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Abivax S.A. (ABVX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.47% | -1.86% | |
| Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) | Press release | PR Newswire | +4.13% | +10.63% | |
| Form 6-K Abivax S.A. For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | +5.09% | -6.18% | |
| Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis | Press release | GlobeNewswire | +5.09% | -6.18% | |
| Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis | Press release | GlobeNewswire | -3.77% | -0.17% | |
| Form 6-K Abivax S.A. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -3.77% | -0.17% | |
| Form 6-K Abivax S.A. For: May 20 | SEC filing · Form 6-K | SEC EDGAR | -0.05% | +4.68% | |
| Abivax Announces Results of its May 11, 2026 Annual General Meeting | Press release | GlobeNewswire | -0.50% | -1.28% | |
| Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares | Press release | GlobeNewswire | -0.79% | -0.38% | |
| Abivax to Present Data on Obefazimod at Digestive Disease Week® | Press release | GlobeNewswire | +0.83% | -1.96% | |
| Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents | Press release | GlobeNewswire | +0.60% | -3.11% | |
| Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | Press release | GlobeNewswire | +1.78% | +5.69% | |
| Abivax Announces Full Year 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.14% | -5.16% | |
| Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | Press release | GlobeNewswire | +1.29% | +3.60% | |
| Abivax Provides 2026 Corporate Outlook | Press release | GlobeNewswire | -1.05% | -7.68% | |
| Abivax to be Added to Nasdaq Biotechnology Index | Press release | GlobeNewswire | +0.21% | -1.80% | |
| Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings | Press release | GlobeNewswire | +2.57% | -0.33% | |
| Abivax Presents Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.48% | -1.79% | |
| Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis | Press release | GlobeNewswire | +0.45% | -0.16% | |
| Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | Press release | GlobeNewswire | +0.01% | -2.62% | |
| Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data | Press release | GlobeNewswire | +0.01% | -2.62% | |
| Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting | Press release | GlobeNewswire | +0.01% | +1.08% | |
| Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting | Press release | GlobeNewswire | -0.13% | -1.43% | |
| Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review | Press release | GlobeNewswire | -0.14% | +0.91% | |
| Abivax Presents First Half 2025 Financial Results | Press release | GlobeNewswire | +1.02% | -0.17% | |
| Abivax Announces Closing of $747.5 Million Public Offering | Press release | GlobeNewswire | +0.31% | — | |
| Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) | Press release | GlobeNewswire | -0.16% | -2.22% | |
| Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares | Press release | GlobeNewswire | +3.02% | +1.00% | |
| Abivax announces temporary trading halt of its ordinary shares on Euronext Paris | Press release | GlobeNewswire | +3.02% | +1.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABVX section they belong to.
Where else ABVX is measured.
ABVX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Abivax SA's median reaction calculated?
Every labeled ABVX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 97 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of ABVX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ABVX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.